{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:24:46Z","timestamp":1794245086776,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Mundipharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13722-017-0071-3","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T23:03:53Z","timestamp":1487891033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence"],"prefix":"10.1186","volume":"12","author":[{"given":"Mersha","family":"Chetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Kenworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Langham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C. N.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"71_CR1","first-page":"1","volume":"11","author":"M Connock","year":"2007","unstructured":"Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1\u2013171.","journal-title":"Health Technol Assess"},{"key":"71_CR2","unstructured":"United Nations World Drug Report. Recent statistics and trend analysis of illicit drug market. 2012. https:\/\/www.unodc.org\/documents\/data-and-analysis\/WDR2012\/WDR_2012_Chapter1.pdf . Accessed 23 Jun 2015."},{"key":"71_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/09595230500286039","volume":"24","author":"J Ross","year":"2005","unstructured":"Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005;24:411\u20138.","journal-title":"Drug Alcohol Rev"},{"key":"71_CR4","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. http:\/\/www.who.int\/substance_abuse\/publications\/opioid_dependence_guidelines.pdf . Accessed 28 May 2015."},{"key":"71_CR5","unstructured":"Doran C. Economic evaluation of interventions for illicit opioid dependence: a review of evidence. 2007. http:\/\/www.who.int\/substance_abuse\/activities\/economic_evaluation_interventions.pdf . Accessed 18 Nov 2015."},{"key":"71_CR6","unstructured":"BMA Board of Science. Drugs of dependence (full report). Chapter 3\u2014the burden of illicit drug use. 2013. http:\/\/bma.org.uk\/news-views-analysis\/in-depth-drugs-of-dependence\/full-report . Accessed 26 Jun 2015."},{"key":"71_CR7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1360-0443.2003.00664.x","volume":"99","author":"M Barnard","year":"2004","unstructured":"Barnard M, McKeganey N. The impact of parental problem drug use on children: what is the problem and what can be done to help? Addiction. 2004;99:552\u20139.","journal-title":"Addiction"},{"key":"71_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/SAR.S45585","volume":"6","author":"M Soyka","year":"2015","unstructured":"Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1\u201314.","journal-title":"Subst Abuse Rehabil"},{"key":"71_CR9","unstructured":"Institute for Clinical and Economic Review. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options 2014. https:\/\/icer-review.org\/wpcontent\/uploads\/2016\/01\/CEPAC-Opioid-Dependence-Final-Report-For-Posting-July-211 . Accessed 28 May 2015."},{"key":"71_CR10","unstructured":"University of Glasgow, Department of General Practice. Critical appraisal checklist for economic evaluations. 2015. http:\/\/www.gla.ac.uk\/media\/media_64048_en.pdf Accessed 3 Jun 2015."},{"key":"71_CR11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1360-0443.1999.9444793.x","volume":"94","author":"PG Barnett","year":"1999","unstructured":"Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction. 1999;94:479\u201388.","journal-title":"Addiction"},{"key":"71_CR12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1360-0443.2001.96912676.x","volume":"96","author":"PG Barnett","year":"2001","unstructured":"Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96:1267\u201378.","journal-title":"Addiction"},{"key":"71_CR13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","volume":"99","author":"CL Masson","year":"2004","unstructured":"Masson CL, Barnett PG, Sees KL, Delucchi KL, Rosen A, Wong W, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction. 2004;99:718\u201326.","journal-title":"Addiction"},{"key":"71_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.drugpo.2004.04.001","volume":"15","author":"CL Miller","year":"2004","unstructured":"Miller CL, Schechter MT, Wood E, Spittal PM, Li K, Laliberte N, et al. The potential health and economic impact of implementing a medically prescribed heroin program among Canadian injection drug users. Int J Drug Policy. 2004;15:259\u201363.","journal-title":"Int J Drug Policy"},{"key":"71_CR15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hec.1056","volume":"15","author":"MA Negrin","year":"2006","unstructured":"Negrin MA, Vazquez-Polo FJ. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. Health Econ. 2006;15:363\u201372.","journal-title":"Health Econ"},{"key":"71_CR16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","volume":"27","author":"BR Schackman","year":"2012","unstructured":"Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27:669\u201376.","journal-title":"J Gen Intern Med"},{"key":"71_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09595230412331289419","volume":"23","author":"IG Sheerin","year":"2004","unstructured":"Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev. 2004;23:261\u201372.","journal-title":"Drug Alcohol Rev"},{"key":"71_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1360-0443.2011.03656.x","volume":"107","author":"JH Stephen","year":"2012","unstructured":"Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction. 2012;107:624\u201334.","journal-title":"Addiction"},{"key":"71_CR19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/17441692.2012.736259","volume":"7","author":"BX Tran","year":"2012","unstructured":"Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. The cost-effectiveness and budget impact of Vietnam\u2019s methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. Glob Public Health. 2012;7:1080\u201394.","journal-title":"Glob Public Health"},{"key":"71_CR20","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2105\/AJPH.90.7.1100","volume":"90","author":"GS Zaric","year":"2000","unstructured":"Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100\u201311.","journal-title":"Am J Public Health"},{"key":"71_CR21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1287\/mnsc.46.8.1013.12025","volume":"46","author":"GS Zaric","year":"2000","unstructured":"Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV prevention: a cost-effectiveness analysis. Manag Sci. 2000;46:1013\u201331.","journal-title":"Manag Sci"},{"key":"71_CR22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/hec.999","volume":"14","author":"GA Zarkin","year":"2005","unstructured":"Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ. 2005;14:1133\u201350.","journal-title":"Health Econ"},{"key":"71_CR23","first-page":"1","volume":"11","author":"Y Adi","year":"2007","unstructured":"Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1\u201385.","journal-title":"Health Technol Assess"},{"key":"71_CR24","unstructured":"Schering-Plough. Manufacturer\u2019s submission. Cited in Connock et al. Health Technol Assess. 2007;11:1\u2013171, iii\u2013iv."},{"key":"71_CR25","unstructured":"Scottish Medicines Consortium. Buprenorphine\/naloxone 2\u00a0mg\/0.5\u00a0mg, 8\/2\u00a0mg sublingual tablet (Suboxone). No. 355\/07. 2007. https:\/\/www.scottishmedicines.org.uk\/files\/buprenorphine_naloxone_sublingual_tablet__Suboxone__355-07_.pdf . Accessed 3 Jun 2015."},{"key":"71_CR26","doi-asserted-by":"crossref","first-page":"A212","DOI":"10.1016\/j.jval.2014.03.1244","volume":"17","author":"E Clay","year":"2014","unstructured":"Clay E, Kharitonova E, Ruby J, Aballea S, Zah V. Medicaid population budget impact analysis of buprenorphine\/naloxone film and tablet formulation. Value Health. 2014;17:A212.","journal-title":"Value Health"},{"key":"71_CR27","first-page":"A213","volume":"17","author":"E Clay","year":"2014","unstructured":"Clay E, Khemiri A, Ruby J, Aballea S, Zah V. A studies-based private insurance budget impact analysis of buprenorphine\/naloxone film and tablet formulations. Value Health. 2014;17:A213.","journal-title":"Value Health"},{"issue":"(1 SUPPL.1)","key":"71_CR28","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.ajog.2012.10.289","volume":"208","author":"J Fowler","year":"2013","unstructured":"Fowler J, Emerson J, Allen A, Dilley S, Gideonse N, Rieckmann T, et al. Buprenorphine vs methadone for maintenance of opioid addiction during pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2013;208((1 SUPPL.1)):S65\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"71_CR29","unstructured":"College voor zorgverzekeringen, Diemen. Guidelines for pharmacoeconomic research, updated version. 2006. http:\/\/www.ispor.org\/PEguidelines\/source\/HTAGuidelinesNLupdated2006.pdf . Accessed 27 Jul 2015."},{"key":"71_CR30","unstructured":"National Institute for Health and Care Excellence. Process and methods guides: guide to the methods of technology appraisal. 2013. http:\/\/www.nice.org.uk\/article\/PMG9\/chapter\/Foreword . Accessed 4 Mar 2015."},{"key":"71_CR31","unstructured":"Norwegian Medicines Agency (NOMA). Guidelines on how to conduct pharmacoeconomic analyses. 2012. http:\/\/www.ispor.org\/PEguidelines\/source\/Norwegian_guidelines2012.pdf . Accessed 27 Jul 2015."},{"key":"71_CR32","unstructured":"Pharmaceutical Benefits Board, Sweden. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). 2003. http:\/\/www.ispor.org\/PEguidelines\/source\/Guidelines_in_Sweden.pdf . Accessed 27 Jul 2015."},{"key":"71_CR33","unstructured":"Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). 2008. http:\/\/www.pbac.pbs.gov.au\/content\/information\/archived-versions\/pbac-guidelines-v4.3-2008.pdf . Accessed 21 Jul 2015."},{"key":"71_CR34","unstructured":"Centers for Disease Control. HIV cost-effectiveness. 2013. http:\/\/www.cdc.gov\/hiv\/prevention\/ongoing\/costeffectiveness\/ . Accessed 18 Nov 2015."}],"container-title":["Addiction Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-017-0071-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:16:09Z","timestamp":1498374969000},"score":1,"resource":{"primary":{"URL":"http:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-017-0071-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1186\/s13722-017-0071-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]},"article-number":"6"}}